Cidofovir: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 1: | Line 1: | ||
== |
==Background== |
||
*Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]] |
*Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]] |
||
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
||
=== |
===Spectrum of Activity=== |
||
* |
*Active against essentially all [[:Category:DNA viruses|DNA viruses]], including polyomaviruses ([[BK virus]], [[JC virus]]), [[human papillomavirus]], [[adenovirus]], all of the [[human herpesviruses]], poxviruses (including [[monkeypox virus]] and [[variola virus]]) |
||
* |
*Not active against h[[Hepatitis B virus|epatitis B virus]] or [[:Category:RNA viruses|RNA viruses]] |
||
=== |
===Pharmacokinetics and Pharmacodynamics=== |
||
* |
*Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
||
== |
==Dosing== |
||
*Should be given with [[probenecid]] 2 g IV prior to each dose |
*Should be given with [[probenecid]] 2 g IV prior to each dose |
||
== |
==Safety== |
||
*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]] |
*Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by [[probenecid]] |
||
Revision as of 17:54, 11 September 2020
Background
- Cytosine nucleotide analogue that inhibits DNA polymerase in human herpesviruses
- Indications: Adenovirus, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus
Spectrum of Activity
- Active against essentially all DNA viruses, including polyomaviruses (BK virus, JC virus), human papillomavirus, adenovirus, all of the human herpesviruses, poxviruses (including monkeypox virus and variola virus)
- Not active against hepatitis B virus or RNA viruses
Pharmacokinetics and Pharmacodynamics
- Unlike ganciclovir, it does not need phosphorylation by UL97
Dosing
- Should be given with probenecid 2 g IV prior to each dose
Safety
- Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid
